Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Iowa Zenbexus Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.06.48

    Zenbexus (iberdomide) Coverage Policy

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.06.48 alerts

    Get alerted when Policy 05.06.48 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical necessity coverage for Zenbexus (iberdomide) for multiple myeloma and specified compendial indications. Coverage requires applicable prior treatment, combination therapy, continuation, and dosing criteria.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyZenbexus (iberdomide) coverage
    Policy CodePolicy 05.06.48
    Change TypeNo material change
    Effective DateOct 16, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization and document the required prior therapy and combination regimen.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsAuthorization period
    1 prior lineMinimum prior therapy
    3Covered indication categories
    1 capsule/dayStandard quantity limit
    1 mg

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    FDA-recommended dose

    Coverage Criteria

    Initial Therapy - Multiple Myeloma

    Authorization of 12 months may be granted for treatment of multiple myeloma when ALL of the following criteria are met:

    ALL of the following

    • Member has received at least one prior line of therapy which included a proteasome inhibitor and an immunomodulatory agent.
    • The requested medication will be used in combination with dexamethasone and daratumumab (Darzalex) or daratumumab and hyaluronidase-fihj (Darzalex Faspro).

    Initial Therapy - Compendial Uses

    Authorization of 12 months may be granted for the treatment of POEMS syndrome, plasma cell-related Monoclonal Immunoglobulin Deposition Disease (MIDD), or plasma cell-related Monoclonal Gammopathy of Renal Significance (MGRS) when ALL of the following criteria are met:

    ALL of the following

    • Member has received at least one prior line of therapy which included a proteasome inhibitor and an immunomodulatory agent.
    • The requested medication will be used in combination with dexamethasone and daratumumab (Darzalex) or daratumumab and hyaluronidase-fihj (Darzalex Faspro).

    Zenbexus (iberdomide) is considered not medically necessary for members who do not meet the criteria set forth above.

    Authorization and Denial Considerations

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Authorization for up to 12 months may be granted for multiple myeloma, POEMS syndrome, plasma cell-related monoclonal immunoglobulin deposition disease (MIDD), or plasma cell-related monoclonal gammopathy of renal significance (MGRS) when all applicable criteria are met.

    • The member has received at least one prior line of therapy that included a proteasome inhibitor and an immunomodulatory agent.
    • Zenbexus will be used in combination with dexamethasone and daratumumab (Darzalex) or daratumumab and hyaluronidase-fihj (Darzalex Faspro).
    Denial Risk

    Criteria Not Met

    Zenbexus (iberdomide) is not medically necessary when the member does not meet the coverage criteria described above.

    Policy Background

    Zenbexus (iberdomide) is covered for adult patients with multiple myeloma who have received at least one prior line of therapy that included both a proteasome inhibitor and an immunomodulatory agent. The FDA-approved regimen combines Zenbexus with dexamethasone and daratumumab or daratumumab and hyaluronidase-fihj. Coverage also recognizes POEMS syndrome, plasma cell-related monoclonal immunoglobulin deposition disease (MIDD), and plasma cell-related monoclonal gammopathy of renal significance (MGRS) as compendial uses when the same prior-treatment and combination-therapy requirements are met.

    Clinical Definitions

    POEMS syndrome
    AcronymPOEMS
    Full definitionPolyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes syndrome
    Policy classificationCompendial use
    MIDD
    AcronymMIDD
    Full definitionPlasma cell-related monoclonal immunoglobulin deposition disease
    Policy classificationCompendial use

    Initial Therapy Authorization

    Initial Therapy - Multiple Myeloma

    Authorization of 12 months may be granted when ALL of the following are met:

    Multiple myeloma

    • Prior treatment: The member has received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.At least 1 prior line
    • Combination treatment: Zenbexus will be used with dexamethasone and daratumumab (Darzalex) or daratumumab and hyaluronidase-fihj (Darzalex Faspro).

    Initial Therapy - Compendial Uses

    Authorization of 12 months may be granted when ALL of the following are met:

    POEMS, MIDD, or MGRS

    Continuation Therapy Authorization

    Continuation Therapy

    Authorization of 12 months may be granted for continued treatment when ALL of the following are met:

    Continuation therapy

    • Covered indication: The member is requesting reauthorization for an indication listed in the coverage criteria section.
    • Clinical response or tolerability: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.

    Quantity and Dosing Limits

    Zenbexus (iberdomide) quantity limit
    MedicationZenbexus (iberdomide)
    Standard limit1 capsule/day
    Limit frequencyPer day
    Zenbexus (iberdomide) FDA-recommended dosing
    MedicationZenbexus (iberdomide)
    FDA-recommended dose1 mg orally once daily on days 1 to 21 of repeated 28 day cycle
    Cycle scheduleDays 1 to 21 of repeated 28 day cycle
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyZenbexus (iberdomide) coverage
    Policy CodePolicy 05.06.48
    Change TypeNo material change
    Effective DateOct 16, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization and document the required prior therapy and combination regimen.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Denial ConsiderationsPolicy BackgroundClinical DefinitionsInitial Therapy AuthorizationContinuation Therapy AuthorizationQuantity and Dosing Limits
    Denial Risk

    Required Prior and Combination Therapy Absent

    Authorization may be denied when documentation does not establish both the required prior therapy and the required combination treatment.

    • At least one prior line of therapy must have included a proteasome inhibitor and an immunomodulatory agent.
    • The requested medication must be used in combination with dexamethasone and daratumumab (Darzalex) or daratumumab and hyaluronidase-fihj (Darzalex Faspro).
    Denial Risk

    Toxicity or Disease Progression

    Continuation authorization may be denied when there is evidence of unacceptable toxicity or disease progression while the member is receiving the current regimen.

    • Reauthorization applies to an indication listed in the coverage criteria section.
    • Continuation authorization is for up to 12 months when there is no evidence of unacceptable toxicity or disease progression.
    MGRS
    AcronymMGRS
    Full definitionPlasma cell-related monoclonal gammopathy of renal significance
    Policy classificationCompendial use
    • Covered indication

      • The member is being treated for POEMS syndrome.
      • The member is being treated for plasma cell-related monoclonal immunoglobulin deposition disease (MIDD).
      • The member is being treated for plasma cell-related monoclonal gammopathy of renal significance (MGRS).
    • Prior treatment: The member has received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.At least 1 prior line
    • Combination treatment: Zenbexus will be used with dexamethasone and daratumumab (Darzalex) or daratumumab and hyaluronidase-fihj (Darzalex Faspro).
    0.75 mg Zenbexus quantity limit
    Medication0.75 mg Zenbexus
    Standard limit1 capsule/day
    Limit frequencyPer day
    0.75 mg Zenbexus FDA-recommended dosing
    Medication0.75 mg Zenbexus
    FDA-recommended dosing.
    Dosing value statusBlank in the document
    Zenbexus (iberdomide) 1 mg quantity limit
    MedicationZenbexus (iberdomide) 1 mg
    Standard limit1 capsule/day
    Limit frequencyPer day
    Zenbexus (iberdomide) 1 mg FDA-recommended dosing
    MedicationZenbexus (iberdomide) 1 mg
    FDA-recommended dosing.
    Dosing value statusBlank in the document